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Abstract
Globally, asthma is a chronic inflammatory respiratory disease affecting over 300 million
people. Some asthma patients remain poorly controlled by conventional therapies and
experience more life-threatening exacerbations. Vitamin D, as an adjunct therapy, may
improve disease control in severe asthma patients since vitamin D enhances glucocorticoid
responsiveness and mitigates airway smooth muscle (ASM) hyperplasia. We sought to
characterize differences in transcriptome responsiveness to vitamin D between fatal
asthma- and non-asthma-derived ASM by using RNA-Seq to measure ASM transcript
expression in five donors with fatal asthma and ten non-asthma-derived donors at baseline
and with vitamin D treatment. Based on a Benjamini-Hochberg corrected p-value <0.05,
838 genes were differentially expressed in fatal asthma vs. non-asthma-derived ASM at
baseline, and vitamin D treatment compared to baseline conditions induced differential
expression of 711 and 867 genes in fatal asthma- and non-asthma-derived ASM, respec-
tively. Functional gene categories that were highly represented in all groups included
extracellular matrix, and responses to steroid hormone stimuli and wounding. Genes differ-
entially expressed by vitamin D also included cytokine and chemokine activity categories.
Follow-up qPCR and individual analyte ELISA experiments were conducted for four cyto-
kines (i.e. CCL2, CCL13, CXCL12, IL8) to measure TNFα-induced changes by asthma sta-
tus and vitamin D treatment. Vitamin D inhibited TNFα-induced IL8 protein secretion levels
to a comparable degree in fatal asthma- and non-asthma-derived ASM even though IL8
had significantly higher baseline levels in fatal asthma-derived ASM. Our findings identify
vitamin D-specific gene targets and provide transcriptomic data to explore differences in the
ASM of fatal asthma- and non-asthma-derived donors.
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Introduction
Asthma, a chronic inflammatory respiratory disease, is defined by increased airway responsive-
ness and inflammation to specific environmental stimuli [1]. Clinical therapy following estab-
lished guidelines successfully controls asthma symptoms in most patients [2]. Such therapy
includes use of glucocorticoids, anti-inflammatory medications [3], and β2-agonists that pro-
mote bronchodilation [4]. Up to 5% of asthma patients, however, are estimated to inadequately
respond to conventional approaches, and consequently, are at greater risk of suffering life-
threatening asthma exacerbations [5]. While patients with severe, refractory disease represent a
heterogeneous group, features shared by most are glucocorticoid insensitivity and, in part, irre-
versible airflow obstruction [6].
Low vitamin D levels are associated with decreased lung function and increased asthma
exacerbations and medication use, although it is unclear whether there is a causal relationship
among these observations or whether asthma patients can benefit from vitamin D supplemen-
tation [7]. Mechanisms by which vitamin D may ameliorate the asthma diathesis include mod-
ulating inflammation by increasing CD4+ T cell synthesis of IL-10 [8], suppressing Th17
cytokines in PBMCs [9], and increasing the number of regulatory T cells [10]. These anti-
inflammatory effects of vitamin D extend to structural cells, including the airway smooth mus-
cle (ASM). For example, vitamin D reduced TNFα-induced CCL5 (RANTES) and CXCL10
(IP-10) secretion in ASM cells, while secretion of CX3CL1 (fractalkine), which is glucocorti-
coid-insensitive, was also decreased by vitamin D treatment [11]. Others found that vitamin
D decreased expression of KPNA4 (importin α3), a signaling molecule for NFκB-induced
inflammation in the ASM [12]. Vitamin D anti-inflammatory effects are, in part, mediated by
enhancing the action of glucocorticoids, suggesting that vitamin D supplementation may bene-
fit patients with glucocorticoid-insensitive asthma [7].
Airway remodeling, an important feature of severe persistent asthma that includes ASM
hyperplasia, is modulated by vitamin D since growth factor-induced ASM proliferation was
inhibited by vitamin D treatment [13,14]. Children with severe, therapy-resistant asthma also
manifested lower levels of vitamin D than children with moderate asthma; endobronchial
biopsies showed an inverse relationship of vitamin D levels and ASMmass, but not epithelial
shedding, reticular basement membrane thickness, or airway inflammation measures [15].
Accordingly, the beneficial vitamin D effects on the ASMmay extend beyond the enhancement
of glucocorticoid actions since glucocorticoids have little effect on airway remodeling or ASM
proliferation [11].
Vitamin D (1,25(OH)2D3) plays a pivotal role in the regulation of gene transcription [16].
Consequently, the study of vitamin D effects on gene transcription in multiple cell types may
reveal changes in signaling pathways that are relevant to specific diseases. For example, a
microarray study that used vitamin D-treated ASM cells from a single male donor without
asthma identified transcription changes in gene categories that might influence airway remod-
eling, including morphogenesis, cell growth and cell survival [17]. Recent advances in sequenc-
ing technologies provide comprehensive and in-depth characterization of transcriptomes via
RNA-Seq [18]. Compared to the use of microarrays, RNA-Seq offers advantages by examining
greater numbers of RNA species over a wider dynamic range of signal [19].
In this study, we used RNA-Seq to identify differences between the transcriptomes of
ASM derived from fatal asthma and non-asthma donors to vitamin D treatment, and we also
specifically examined four cytokines (i.e. CCL2, CCL13, CXCL12, IL8) whose expression dif-
fered between fatal asthma- and non-asthma-derived ASM at baseline and with vitamin D
treatment.
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Results
Transcriptomic Differences Between Fatal Asthma- and Non-Asthma-
Derived ASM
After quality control processing, 30 samples were selected for differential expression analysis.
Such samples corresponded to 5 fatal asthma and 10 non-asthma donors with vitamin D or
control vehicle treatment [Table 1]. Comparison of fatal asthma-derived vs. non-asthma-
derived ASM at baseline revealed that 838 genes were significantly differentially expressed
according to a 0.05 false discovery rate threshold (i.e. q-value< 0.05) [Fig A in S1 Fig]. Dif-
ferentially expressed genes were prioritized by (1) selecting the 370 genes with the lowest q-
value of 1.92E-03, (2) selecting the subset of 192 of these genes with magnitude of Log2 fold-
change>1.3, and (3) dropping genes for which at least two individual samples did not have
FPKM values>5 [Table 2]. Among the top genes are ones that have been previously related
to asthma (e.g., APOE [20], CHI3L1 [21], EGR1 [22],MYH11 [23], OXTR [24], SERPINB2
[25,26], SOCS3 [27]) and corticosteroid-resistant asthma (e.g., FOS [28]) though not neces-
sarily in humans or via changes of the ASM. Additionally, there were many novel genes that
have not been previously related to asthma phenotypes. To gain a better sense of the biologi-
cal functions represented by the 838 differentially expressed genes, we performed an ontolog-
ical category enrichment analysis using the NIH DAVID tool [29]. There were 24 annotation
clusters with enrichment scores >2.50 [S1 Table]. Among these clusters, some of the individ-
ual enrichment categories had Benjamini-Hochberg adjusted p-values < 0.05 and referred to
specific biological structures or processes that are associated with asthma: immunoglobulin
domain, lung development, response to steroid hormone stimulus, response to wounding,
extracellular matrix, and response to oxidative stress. S2 Table contains the gene members
for these categories and two that were significant in vitamin D treated ASM cells vs. ASM
cells at baseline.
Table 1. Characteristics of ASM donors. All donors were white non-smokers. There were no significant dif-
ferences between sex, age, or BMI of fatal asthma- vs. non-asthma-derived donors. Medical examiner ruled
cause of death for fatal asthma donors was “Asthma Attack/Anoxia,” or a significant asthma event is listed as
preceding death.
Fatal Asthma (N = 5) Non-Asthma (N = 10)
Sex
Male 2 6
Female 3 4
Age
Mean (SD) 31.2 (20.1) 33.1 (15.2)
[Range] [9, 59] [17, 52]
BMI
Mean (SD) 27.4 (6.5) 27.4 (6.5)
[Range] [17.9, 34.5] [21.5, 40.5]
Cause of Death
CVA - 2
Head Trauma - 4
Anoxia - 3
AVM rupture - 1
doi:10.1371/journal.pone.0134057.t001
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Table 2. Top differentially expressed genes in fatal asthma- vs. non-asthma-derived ASM at baseline. FPKM = fragments per kilobase of transcript
per million mapped reads. All genes in list have q-value = 1.92E-03, magnitude Log2(Fold Change) >1.30, and at least two individual samples with FPKM >5.
Gene Locus Mean FPKM Non-Asthma Mean FPKM Fatal Asthma Log2[Fold Change]
SERPINB2 chr18:61554938–61571124 0.41 39.18 6.57
FOS chr14:75745480–75748937 56.13 0.66 -6.42
HBD chr11:5254058–5255858 0.94 24.31 4.70
EGR1 chr5:137801180–137805004 232.04 11.36 -4.35
MYH11 chr16:15737123–15950887 8.15 0.46 -4.14
CHI3L1 chr1:203148058–203155922 57.11 4.21 -3.76
SFRP2 chr4:154701741–154710228 7.44 0.63 -3.57
DES chr2:220283098–220291461 13.82 1.29 -3.42
HLA-C chr6:31236525–31239913 18.62 1.85 -3.33
EGR2 chr10:64571755–64578927 2.99 0.36 -3.07
IFI6 chr1:27992571–27998724 57.11 461.09 3.01
IFI27 chr14:94577078–94583033 8.88 65.13 2.88
A2M chr12:9217772–9268558 341.16 46.75 -2.87
EGR3 chr8:22545173–22550815 3.72 0.54 -2.79
SCUBE3 chr6:35182189–35218609 1.02 6.94 2.76
TINAGL1 chr1:32042085–32053287 1.69 10.99 2.70
PDLIM3 chr4:186421814–186456712 4.63 0.73 -2.67
SYPL2 chr1:110009099–110024764 1.14 7.03 2.63
RARRES1 chr3:158414896–158450275 119.42 20.05 -2.57
PSG4 chr19:43696853–43709790 23.85 138.94 2.54
SOCS3 chr17:76352858–76356158 111.55 20.00 -2.48
APOE chr19:45409038–45412650 99.29 18.03 -2.46
B4GALNT4 chr11:369794–382117 7.42 1.41 -2.39
TM4SF20 chr2:228226873–228244022 0.75 3.93 2.38
NPAS1 chr19:47524142–47549017 0.69 3.51 2.35
JUNB chr19:12902309–12904125 132.22 26.05 -2.34
PTGS2 chr1:186640943–186649559 5.40 1.06 -2.34
MX1 chr21:42792519–42831141 3.79 18.85 2.32
IL8 chr4:74606222–74609433 0.87 4.31 2.31
PPP1R1B chr17:37783176–37792878 7.63 1.54 -2.31
IGFBP7 chr4:57845108–58071465 141.30 673.27 2.25
ACTG2 chr2:74120092–74146780 41.93 8.95 -2.23
HLA-B chr6:31321648–31324989 42.92 9.34 -2.20
TEK chr9:27109146–27230172 1.28 5.82 2.19
OXTR chr3:8792094–8811300 5.32 23.54 2.15
SCN4B chr11:118004091–118023630 4.44 1.01 -2.14
CCL13 chr17:32683470–32685629 1.31 5.62 2.10
NDNF chr4:121956781–121993673 4.00 0.96 -2.06
TFAP2A chr6:10396915–10419797 1.73 7.13 2.05
NR4A1 chr12:52416615–52453291 17.27 4.21 -2.04
OLR1 chr12:10310898–10324790 2.49 10.19 2.03
IER2 chr19:13261281–13265718 68.06 16.68 -2.03
CPNE7 chr16:89642175–89663654 1.61 6.27 1.96
CERS4 chr19:8274216–8327304 10.96 2.86 -1.94
CECR1 chr22:17660191–17690779 13.18 3.44 -1.94
CES1 chr16:55836763–55867075 59.97 15.70 -1.93
(Continued)
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Table 2. (Continued)
Gene Locus Mean FPKM Non-Asthma Mean FPKM Fatal Asthma Log2[Fold Change]
ISG15 chr1:948846–949919 28.51 108.61 1.93
SPON1 chr11:13984183–14289679 8.25 2.17 -1.93
PSG5 chr19:43671894–43690688 50.63 191.94 1.92
FNDC1 chr6:159590428–159693140 4.85 1.29 -1.91
FMO2 chr1:171154387–171181822 14.66 3.93 -1.90
SERPINA3 chr14:95078713–95090390 29.20 7.89 -1.89
PEAR1 chr1:156863522–156886226 2.69 9.73 1.86
RASL12 chr15:65337707–65360388 24.77 6.86 -1.85
ADAMTS5 chr21:28290230–28339439 5.87 20.98 1.84
ABCG1 chr21:43619798–43717354 6.48 1.83 -1.82
GDF10 chr10:48425787–48439138 102.61 29.10 -1.82
SGCG chr13:23755059–23899304 1.82 6.42 1.82
AEBP1 chr7:44143959–44154159 144.69 41.17 -1.81
CCKAR chr4:26483017–26492042 31.20 9.09 -1.78
SHC2 chr19:416582–460996 10.66 3.11 -1.78
HSD17B6 chr12:57157107–57181574 7.60 25.93 1.77
ALPK2 chr18:56148481–56296189 2.15 7.31 1.76
PSG1 chr19:43370612–43383871 4.13 13.95 1.76
GPRC5A chr12:13043955–13066600 6.30 21.17 1.75
LOC645638 chr17:58160926–58165828 11.94 39.70 1.73
PTGDS chr9:139871955–139876194 433.66 134.15 -1.69
MYOC chr1:171604556–171621773 13.18 4.13 -1.67
MFAP5 chr12:8798539–8815433 26.25 82.96 1.66
TBX4 chr17:59533806–59561664 18.10 5.73 -1.66
CHI3L2 chr1:111770280–111786062 46.33 14.69 -1.66
BAMBI chr10:28966423–28971868 5.68 17.73 1.64
GNG2 chr14:52327021–52436518 5.04 1.63 -1.63
MARCH4 chr2:217122584–217236750 3.17 9.32 1.56
DMKN chr19:35988118–36004560 39.40 13.56 -1.54
CPA4 chr7:129932973–129964020 3.08 8.90 1.53
KRT7 chr12:52626953–52642709 13.56 39.15 1.53
COL14A1 chr8:121137351–121384273 35.38 12.27 -1.53
PLCB4 chr20:9049700–9461462 3.51 10.06 1.52
SLC2A1 chr1:43391045–43449029 33.40 95.72 1.52
STEAP3 chr2:119981383–120023227 4.57 12.99 1.51
GLT25D2 chr1:183904965–184006863 2.27 6.43 1.50
TFPI2 chr7:93515744–93520065 4.81 13.47 1.49
PCSK2 chr20:17206751–17465222 7.50 2.68 -1.49
DKK1 chr10:54074040–54077417 17.41 47.95 1.46
ITGA6 chr2:173292313–173371181 1.81 4.98 1.46
CLEC3B chr3:45067758–45077563 47.23 129.11 1.45
FGFR4 chr5:176513920–176525126 6.56 2.43 -1.43
CSRNP1 chr3:39183341–39195102 5.77 2.15 -1.42
SLC7A5 chr16:87863628–87903100 14.64 39.01 1.41
GPC3 chrX:132669775–133119673 29.19 11.03 -1.40
WISP2 chr20:43343884–43356452 46.81 17.71 -1.40
RGMA chr15:93586635–93632443 11.83 4.53 -1.38
(Continued)
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Influence of Vitamin D on the Transcriptome of Fatal Asthma- and Non-
Asthma-Derived ASM
Comparison of genes expressed in ASM when treated with vitamin D vs. baseline revealed that
867 genes were differentially expressed in non-asthma-derived ASM, while 711 genes were dif-
ferentially expressed in fatal asthma-derived ASM, in response to vitamin D treatment [Figs B
and C in S1 Fig]. A subset of 307 genes was vitamin D responsive in both fatal asthma- and
non-asthma-derived ASM. As for the fatal asthma- vs. non-asthma-derived comparison, differ-
entially expressed genes were prioritized by (1) selecting the genes with the lowest q-value of
1.92E-03 (n = 394 for non-asthma-derived ASM; n = 345 for fatal asthma-derived ASM), (2)
selecting the subset of these genes with magnitude of Log2 fold-change>1.3 (n = 105 for non-
asthma-derived ASM; n = 214 for fatal asthma-derived ASM), and (3) dropping genes for
which at least two individual samples did not have FPKM values>5 [Tables 3 and 4].
To gain a better sense of biological functions represented by the differentially expressed
genes, we performed an ontological category enrichment analysis using the NIH DAVID tool
[29]. For the non-asthma-derived ASM at baseline vs. vitamin D treated comparison, there
with 24 annotation clusters with enrichment scores>2.50 [S3 Table]. For the fatal asthma-
derived ASM at baseline vs. vitamin D treated comparison, there with 21 annotation clusters
with enrichment scores>2.50 [S4 Table]. Some of the individual asthma-related enrichment
categories within clusters with Benjamini-Hochberg adjusted p-values< 0.05 were also present
in the fatal asthma- vs. non-asthma-derived comparison: extracellular matrix, immunoglobulin
domain, response to steroid hormone stimulus, and response to wounding [S5 and S6 Tables],
although some genes within categories differed. The oxidative stress and lung development
categories were still significant for the non-asthma-derived ASM treated with vitamin D vs.
baseline but not for the fatal asthma-derived ASM treated with vitamin D vs. baseline. Two
asthma-related categories that were not present in the fatal asthma- vs. non-asthma-derived
ASM comparison were significant in both the vitamin D treated vs. baseline comparisons: cyto-
kine activity and chemokine activity [S5 and S6 Tables].
Table 2. (Continued)
Gene Locus Mean FPKM Non-Asthma Mean FPKM Fatal Asthma Log2[Fold Change]
TUFT1 chr1:151512780–151556059 4.50 11.74 1.38
LOC728392 chr17:5402746–5404319 29.62 76.86 1.38
F3 chr1:94994731–95007413 18.63 48.32 1.37
SLC7A11 chr4:138948576–139163503 5.71 14.80 1.37
SERPINE1 chr7:100770378–100782547 118.50 306.35 1.37
PDPN chr1:13910251–13944452 9.84 3.82 -1.37
SULF2 chr20:46286149–46415360 33.96 13.21 -1.36
IL32 chr16:3115312–3119668 25.90 66.18 1.35
DCHS1 chr11:6642557–6677074 6.65 2.62 -1.34
CHRM2 chr7:136553398–136849088 15.63 39.61 1.34
TLE2 chr19:2997635–3047633 6.74 2.67 -1.34
BST2 chr19:17513754–17516384 8.51 21.35 1.33
COLEC12 chr18:319354–500729 68.62 27.44 -1.32
RSPO1 chr1:38076950–38100595 7.77 3.11 -1.32
ARHGAP28 chr18:6834431–6915712 5.49 2.21 -1.32
PTPRD chr9:8314245–10612723 4.92 1.99 -1.31
SNHG5 chr6:86386724–86388451 488.49 198.98 -1.30
doi:10.1371/journal.pone.0134057.t002
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Table 3. Top differentially expressed genes in non-asthma-derived ASM at baseline vs. when treated with vitamin D. FPKM = fragments per kilobase
of transcript per million mapped reads. All genes in list have q-value = 1.92E-03, magnitude Log2(Fold Change) >1.30, and at least two individual samples
with FPKM >5.
Gene Locus Mean FPKM Non-Asthma Baseline Mean FPKM Non-Asthma Vit D Log2[Fold Change]
CYP24A1 chr20:52769987–52790516 0.25 157.66 9.30
CXCL6 chr4:74702272–74704477 9.35 0.35 -4.73
CRIP1 chr14:105953256–105955124 3.06 41.77 3.77
FOS chr14:75745480–75748937 56.13 4.84 -3.53
CXCL1 chr4:74735108–74737019 7.64 0.66 -3.53
CYP3A5 chr7:99245812–99277621 0.22 2.41 3.42
HBA2 chr16:222845–223709 7.87 0.74 -3.42
G0S2 chr1:209848669–209849735 6.09 61.25 3.33
IGFLR1 chr19:36230150–36233351 1.85 16.73 3.18
CILP chr15:65488336–65503840 3.22 24.30 2.91
PTGS2 chr1:186640943–186649559 5.40 0.79 -2.76
THBD chr20:23026269–23030301 0.31 1.97 2.69
HBB chr11:5246695–5248301 12.56 1.98 -2.66
EGR1 chr5:137801180–137805004 232.04 37.68 -2.62
TM7SF2 chr11:64879340–64883707 4.60 27.11 2.56
IDH2 chr15:90627211–90645708 21.35 120.25 2.49
CCL7 chr17:32597239–32599256 3.34 0.65 -2.35
CCKAR chr4:26483017–26492042 31.20 6.64 -2.23
NGEF chr2:233743395–233877951 0.32 1.49 2.20
C15orf48 chr15:45722762–45725647 1.16 5.28 2.19
LGALS9 chr17:25958173–25976586 1.40 6.01 2.10
SLPI chr20:43880878–43883206 3.13 12.17 1.96
EGR2 chr10:64571755–64578927 2.99 0.81 -1.89
TGFB3 chr14:76424441–76448092 3.46 12.80 1.89
EFTUD1 chr15:82422560–82555104 5.55 20.44 1.88
OAF chr11:120081746–120100650 80.02 290.60 1.86
CCL11 chr17:32612686–32615199 45.36 12.76 -1.83
FZD8 chr10:35927176–35930362 1.21 4.21 1.80
SLC1A3 chr5:36606456–36688436 1.66 5.72 1.78
NFKBIZ chr3:101498028–101579869 11.86 3.54 -1.75
IL13RA2 chrX:114238537–114252207 7.77 2.33 -1.73
EGR3 chr8:22545173–22550815 3.72 1.12 -1.73
HMCN1 chr1:185703682–186446655 2.43 7.97 1.71
NR4A1 chr12:52416615–52453291 17.27 5.30 -1.70
CCL2 chr17:32582295–32584220 166.20 51.14 -1.70
SFRP2 chr4:154701741–154710228 7.44 24.17 1.70
SYT7 chr11:61281187–61348344 2.66 8.53 1.68
SPINT2 chr19:38755097–38783254 1.53 4.83 1.65
DUSP5 chr10:112257624–112271302 14.73 4.76 -1.63
FER1L6 chr8:124864226–125132302 0.99 3.05 1.62
ACAN chr15:89346673–89418585 0.70 2.15 1.62
FAIM2 chr12:50260678–50297760 2.62 7.92 1.60
CYR61 chr1:86046443–86049648 370.72 128.01 -1.53
SOCS3 chr17:76352858–76356158 111.55 38.80 -1.52
SLC14A1 chr18:43304091–43332485 1.48 4.20 1.50
(Continued)
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TNFα Responsiveness of Select Cytokines Measured by q-PCR
Four genes (i.e. CCL2, CCL13, CXCL12, IL8) that (1) were members of the GO:0008009~chem-
okine activity ontological category, which was significantly over-represented among genes
differentially expressed in response to vitamin D treatment in both fatal asthma- and non-
asthma-derived ASM [S5 and S6 Tables], and (2) were differentially expressed in fatal asthma
vs. non-asthma-derived ASM at baseline [S2 Table] were selected for detailed examination
[Fig 1; Table 5]. Differential expression for these four genes at baseline and with vitamin D
treatment was measured via qRT-PCR. No statistically significant differences in mRNA expres-
sion between fatal asthma- and non-asthma-derived ASM at baseline were found (data not
shown). Fold changes for CCL2 and CXCL12 expression with vitamin D treatment vs. baseline
were consistent with RNA-Seq results for most samples, while CCL13 and IL8 had consistent
effects for only some samples [Fig 2]. We found that TNFα treatment induced CCL2, CCL13,
and IL8mRNA expression in most fatal asthma- and non-asthma-derived ASM samples, but
TNFα treatment did not induce CXCL12 [Fig 2]. Vitamin D decreased the mean TNFα-
induced CCL2, CCL13, and IL8mRNA expression in most ASM groups, but this change was
not statistically significant or consistent across all samples [Fig 2].
Characterization of Cytokine Secretion and Sensitivity to Vitamin D
Our RNA-Seq results suggested that mRNA for four cytokines were differentially expressed in
ASM derived from fatal asthma vs. non-asthma donors at baseline and with vitamin D treat-
ment. To address whether these differences in mRNA extended to changes in protein secretion,
individual analyte ELISAs for the four selected cytokines (i.e. CCL2 (aka MCP-1), CCL13 (aka
MCP-4), CXCL12 (aka SDF-1) and IL8) were performed. At baseline, CCL2 and CXCL12 were
Table 3. (Continued)
Gene Locus Mean FPKM Non-Asthma Baseline Mean FPKM Non-Asthma Vit D Log2[Fold Change]
H19 chr11:2016405–2019065 13.48 37.13 1.46
SHISA3 chr4:42399855–42404504 1.58 4.34 1.46
OSR1 chr2:19551245–19558372 20.37 55.38 1.44
CYP3A7 chr7:99282301–99332819 1.34 3.63 1.44
SLMO1 chr18:12407894–12432236 3.08 8.34 1.44
SORCS2 chr4:7194373–7744564 0.94 2.51 1.42
CD248 chr11:66081957–66084515 286.58 764.29 1.42
NTRK2 chr9:87283465–87638505 1.08 2.88 1.41
SEMA3B chr3:50305039–50314572 29.16 76.45 1.39
CNIH3 chr1:224804178–224928249 2.87 7.44 1.37
ALPL chr1:21835857–21904905 8.46 21.91 1.37
DDIT4 chr10:74033676–74035797 37.93 98.15 1.37
PRSS35 chr6:84222193–84235421 7.74 3.00 -1.37
PSG1 chr19:43370612–43383871 4.13 1.61 -1.36
ITPR1 chr3:4535031–4889524 5.69 14.44 1.34
SMTNL2 chr17:4487275–4511614 1.69 4.29 1.34
APBB1IP chr10:26727265–26856732 5.15 12.84 1.32
MAPK13 chr6:36098261–36107842 2.90 7.21 1.31
RHOU chr1:228780393–228882416 3.14 7.78 1.31
MYOC chr1:171604556–171621773 13.18 5.37 -1.30
SCARA5 chr8:27727398–27850369 3.20 7.86 1.30
doi:10.1371/journal.pone.0134057.t003
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Table 4. Top differentially expressed genes in fatal asthma-derived ASM at baseline vs. when treated with vitamin D. FPKM = fragments per kilobase
of transcript per million mapped reads. All genes in list have q-value = 1.92E-03, magnitude Log2(Fold Change) >1.30, and at least two individual samples
with FPKM >5.
Gene Locus Mean FPKM Fatal Asthma Baseline Mean FPKM Fatal Asthma Vit D Log2[Fold Change]
HBD chr11:5254058–5255858 24.31 0.58 -5.39
SERPINB2 chr18:61554938–61571124 39.18 1.10 -5.16
IL8 chr4:74606222–74609433 4.31 0.16 -4.79
CXCL1 chr4:74735108–74737019 14.18 0.68 -4.37
CILP chr15:65488336–65503840 1.31 24.45 4.22
RMRP chr9:35657747–35658015 4.64 81.69 4.14
RPPH1 chr14:20811229–20811570 2.21 30.69 3.80
CYP3A7 chr7:99282301–99332819 0.62 8.02 3.69
IGFLR1 chr19:36230150–36233351 1.22 14.72 3.59
CHRDL2 chr11:74407473–74442186 0.76 7.35 3.28
CRIP1 chr14:105953256–105955124 3.87 36.71 3.25
APLN chrX:128779235–128788933 0.91 7.46 3.04
IFI6 chr1:27992571–27998724 461.09 56.11 -3.04
MX1 chr21:42792519–42831141 18.85 2.31 -3.03
SLC1A3 chr5:36606456–36688436 0.91 7.38 3.02
G0S2 chr1:209848669–209849735 4.72 37.54 2.99
IGF1 chr12:102789644–102874378 2.82 20.63 2.87
TM4SF20 chr2:228226873–228244022 3.93 0.63 -2.65
FOS chr14:75745480–75748937 0.66 4.00 2.61
SYT7 chr11:61281187–61348344 1.24 7.24 2.54
PCSK2 chr20:17206751–17465222 2.68 15.36 2.52
CD14 chr5:140011312–140013286 0.89 5.04 2.51
IFI27 chr14:94577078–94583033 65.13 11.57 -2.49
SYPL2 chr1:110009099–110024764 7.03 1.33 -2.40
ACAN chr15:89346673–89418585 12.80 2.43 -2.40
AOC3 chr17:41003200–41010140 2.45 12.69 2.38
IDH2 chr15:90627211–90645708 24.40 118.59 2.28
TM7SF2 chr11:64879340–64883707 4.97 23.07 2.21
CCL2 chr17:32582295–32584220 300.27 65.12 -2.21
APOE chr19:45409038–45412650 18.03 82.34 2.19
ELN chr7:73442426–73484236 85.14 388.52 2.19
MAP2 chr2:210288770–210598834 11.95 2.68 -2.16
LEPREL1 chr3:189674516–189840226 4.64 1.05 -2.15
OAF chr11:120081746–120100650 78.06 342.82 2.13
CCL11 chr17:32612686–32615199 67.55 15.46 -2.13
COL14A1 chr8:121137351–121384273 12.27 53.43 2.12
VEGFA chr6:43737945–43754223 32.93 139.20 2.08
EFTUD1 chr15:82422560–82555104 5.67 23.85 2.07
GPRC5A chr12:13043955–13066600 21.17 5.04 -2.07
ANXA3 chr4:79472741–79531605 5.30 1.26 -2.07
IFIT1 chr10:91152321–91163744 30.48 7.31 -2.06
RARRES2 chr7:150035406–150038763 156.60 651.36 2.06
PSG5 chr19:43671894–43690688 191.94 48.03 -2.00
CES1 chr16:55836763–55867075 15.70 62.37 1.99
COL5A3 chr19:10070236–10121147 3.01 11.75 1.97
(Continued)
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Table 4. (Continued)
Gene Locus Mean FPKM Fatal Asthma Baseline Mean FPKM Fatal Asthma Vit D Log2[Fold Change]
TPD52L1 chr6:125474878–125584644 43.06 11.17 -1.95
ITPR1 chr3:4535031–4889524 3.83 14.71 1.94
APOD chr3:195295572–195311076 13.81 52.99 1.94
ISG15 chr1:948846–949919 108.61 28.92 -1.91
ALPL chr1:21835857–21904905 12.61 47.26 1.91
PRSS35 chr6:84222193–84235421 16.34 4.36 -1.91
SPON1 chr11:13984183–14289679 2.17 8.12 1.90
ACTG2 chr2:74120092–74146780 8.95 33.49 1.90
EPSTI1 chr13:43462121–43566377 7.54 2.02 -1.90
RHOU chr1:228780393–228882416 2.03 7.50 1.89
OLR1 chr12:10310898–10324790 10.19 2.78 -1.87
ABCA9 chr17:66970772–67057136 5.06 18.18 1.85
CD274 chr9:5450502–5470567 1.21 4.33 1.84
RASL12 chr15:65337707–65360388 6.86 24.44 1.83
FAIM2 chr12:50260678–50297760 1.39 4.96 1.83
NOV chr8:120428551–120436678 23.67 6.68 -1.83
TGFB3 chr14:76424441–76448092 3.09 10.85 1.81
PSG1 chr19:43370612–43383871 13.95 3.98 -1.81
HTRA3 chr4:8271488–8308838 10.31 35.91 1.80
WISP2 chr20:43343884–43356452 17.71 61.21 1.79
GDF6 chr8:97154557–97173020 0.89 3.07 1.78
SCUBE3 chr6:35182189–35218609 6.94 2.02 -1.78
CXCL12 chr10:44865604–44880545 294.15 1009.51 1.78
AEBP1 chr7:44143959–44154159 41.17 139.15 1.76
IFI44 chr1:79115476–79129763 11.90 3.54 -1.75
DMKN chr19:35988118–36004560 13.56 45.33 1.74
PTGES chr9:132500614–132515344 25.50 7.71 -1.73
SBSN chr19:36014268–36019253 4.46 14.73 1.72
A2M chr12:9217772–9268558 46.75 154.00 1.72
BAMBI chr10:28966423–28971868 17.73 5.39 -1.72
TFPI2 chr7:93515744–93520065 13.47 4.09 -1.72
PSG4 chr19:43696853–43709790 138.94 42.51 -1.71
GDF10 chr10:48425787–48439138 29.10 93.77 1.69
RGMA chr15:93586635–93632443 4.53 14.60 1.69
RSPO1 chr1:38076950–38100595 3.11 9.96 1.68
FNDC1 chr6:159590428–159693140 1.29 4.13 1.68
DDIT4 chr10:74033676–74035797 44.62 141.01 1.66
EGR1 chr5:137801180–137805004 11.36 35.60 1.65
LOC645638 chr17:58160926–58165828 39.70 12.68 -1.65
TGFB2 chr1:218517537–218617961 3.68 11.52 1.64
BHLHE40 chr3:5021096–5026865 7.87 24.35 1.63
TRIB3 chr20:361307–378203 15.39 47.17 1.62
IL13RA2 chrX:114238537–114252207 10.77 3.54 -1.61
ZFP36 chr19:39897486–39900045 50.83 154.60 1.60
BDKRB1 chr14:96722546–96731100 28.88 9.64 -1.58
SULF2 chr20:46286149–46415360 13.21 39.57 1.58
PDPN chr1:13910251–13944452 3.82 11.40 1.58
(Continued)
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Table 4. (Continued)
Gene Locus Mean FPKM Fatal Asthma Baseline Mean FPKM Fatal Asthma Vit D Log2[Fold Change]
HGF chr7:81331443–81399452 30.12 10.18 -1.57
SERPINA3 chr14:95078713–95090390 7.89 23.20 1.56
SIX1 chr14:61111416–61116155 6.62 19.44 1.56
CHI3L2 chr1:111770280–111786062 14.69 43.14 1.55
GPC3 chrX:132669775–133119673 11.03 32.23 1.55
SIK1 chr21:44834397–44847002 2.52 7.29 1.53
IFIT3 chr10:91087601–91100725 37.15 12.95 -1.52
TOX chr8:59717976–60031767 5.66 1.98 -1.52
ALDH1A1 chr9:75515577–75568233 24.38 8.56 -1.51
PLAU chr10:75669726–75682535 34.94 12.30 -1.51
PDGFRL chr8:17433941–17500642 9.04 25.63 1.50
RCAN1 chr21:35888783–35987382 56.39 19.95 -1.50
KIT chr4:55524094–55606881 7.00 2.48 -1.50
TNFAIP3 chr6:138188580–138204449 6.55 2.33 -1.49
PTGDS chr9:139871955–139876194 134.15 376.14 1.49
NQO1 chr16:69743303–69760533 146.93 52.45 -1.49
AK5 chr1:77747661–78025654 8.17 2.92 -1.48
ARHGAP28 chr18:6834431–6915712 2.21 6.16 1.48
EML3 chr11:62369690–62382592 15.39 42.52 1.47
PRPS1 chrX:106871653–106894256 48.46 17.67 -1.46
GCNT4 chr5:74323288–74326724 3.88 1.42 -1.45
OSR2 chr8:99956630–99964326 96.60 262.33 1.44
MAP2K3 chr17:21187967–21218551 50.93 18.95 -1.43
MREG chr2:216807313–216878346 1.92 5.15 1.42
SPRY1 chr4:124317955–124324909 7.20 19.31 1.42
MIR210HG chr11:565656–568457 2.99 8.02 1.42
EGFL6 chrX:13587693–13651694 10.10 27.04 1.42
SDK1 chr7:3341079–4308631 3.00 8.00 1.41
EDNRA chr4:148402068–148466106 1.71 4.55 1.41
RARRES1 chr3:158414896–158450275 20.05 53.09 1.40
LIF chr22:30636441–30642796 4.79 1.81 -1.40
ID3 chr1:23884420–23886285 16.08 6.11 -1.40
IL32 chr16:3115312–3119668 66.18 25.59 -1.37
PCOLCE2 chr3:142536701–142608045 44.82 17.33 -1.37
BST2 chr19:17513754–17516384 21.35 8.27 -1.37
TRNP1 chr1:27320194–27327377 44.79 17.38 -1.37
NCEH1 chr3:172348434–172429008 6.67 2.59 -1.36
ASS1 chr9:133320093–133376661 75.65 29.42 -1.36
C7 chr5:40909598–40983042 6.62 2.58 -1.36
DKK1 chr10:54074040–54077417 47.95 18.78 -1.35
SSX2IP chr1:85109389–85156240 7.20 2.82 -1.35
GCLM chr1:94352589–94375012 44.79 17.60 -1.35
SEMA3A chr7:83587658–83824217 10.51 4.17 -1.33
ATP8B1 chr18:55297533–55470327 24.99 9.96 -1.33
PKDCC chr2:42275160–42285668 31.61 12.62 -1.32
DUSP5 chr10:112257624–112271302 11.06 4.41 -1.32
GREM2 chr1:240652872–240775462 8.10 3.24 -1.32
(Continued)
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secreted differently from fatal asthma and non-asthma derived ASM in directions consistent
with RNA-Seq results, but only those of CXCL12 were statistically significant [Fig 3]. IL8 secre-
tion was not detected at baseline, while that of CCL13 was low and not different between fatal
asthma and non-asthma derived ASM [Fig 3]. Fatal asthma-derived ASM secreted greater
TNFα-induced IL8 and lower TNFα-induced CXCL12 as compared to non-asthma-derived
ASM, while TNFα-induced CCL2, and CCL13 levels between fatal asthma- and non-asthma-
derived ASM were not significantly different [Fig 3]. Overall, TNFα-induced secretion of
CCL13 was low, while that of CCL2 and IL8 were high. Because IL8 was secreted at high levels
that were significantly different between fatal asthma and non-asthma-derived ASM, we tested
the dose-dependent effect of vitamin D on its TNFα-induced secretion. Additionally, CCL5
(aka RANTES), CXCL10 (aka IP-10) were also chosen for comparison experiments because
these chemokines were known mediators in asthma that are differentially sensitive to vitamin
D [11]. As shown in Fig 4, vitamin D inhibited three cytokine levels to a comparable degree in
fatal asthma- vs. non-asthma-derived ASM, even for IL8, whose TNFα-induced baseline
Table 4. (Continued)
Gene Locus Mean FPKM Fatal Asthma Baseline Mean FPKM Fatal Asthma Vit D Log2[Fold Change]
NDRG1 chr8:134249413–134309547 58.01 144.57 1.32
SH2D4A chr8:19171080–19253729 25.97 10.50 -1.31
ADAMTS15 chr11:130318868–130346539 6.27 15.51 1.31
NBL1 chr1:19923470–19984949 165.17 407.92 1.30
doi:10.1371/journal.pone.0134057.t004
Fig 1. RNA-Seq results expressed as FPKM for four cytokine genes (i.e.,CCL2,CCL13,CXCL12, IL8) by condition status. Table 5 lists q-values and
fold changes among comparison groups for these genes.
doi:10.1371/journal.pone.0134057.g001
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Table 5. Differential expression results for all comparison groups corresponding to four cytokine genes that were selected for further study.
Genes were selected based on being (1) members of theGO:0008009~chemokine activity ontological category, which was significantly over-represented
among genes differentially expressed in response to vitamin D treatment in both fatal asthma- and non-asthma-derived ASM, that were (2) differentially
expressed in fatal asthma-derived vs. non-asthma-derived ASM at baseline. FPKM = fragments per kilobase of transcript per million mapped reads.
Fatal Asthma vs.
Non-Asthma at
Baseline
Non-Asthma
Vitamin D vs.
Baseline
Fatal Asthma
Vitamin D vs.
Baseline
Gene Locus Mean
FPKM Non-
Asthma
Baseline
Mean
FPKM Fatal
Asthma
Baseline
Mean
FPKM Non-
Asthma
Vitamin D
Mean
FPKM Fatal
Asthma
Vitamin D
Log2
[Fold
Change]
Q-
value
Log2
[Fold
Change]
Q-
value
Log2
[Fold
Change]
Q-
value
CCL2 chr17:32582295–
32584220
166.2 300.3 51.1 65.1 0.85 1.9E-
03
-1.70 1.9E-
03
-2.21 1.9E-
03
CCL13 chr17:32683470–
32685629
1.31 5.62 0.42 1.49 2.10 1.9E-
03
-1.63 2.9E-
02
-1.91 6.3E-
03
CXCL12 chr10:44865604–
44880545
681.0 294.2 912.2 1009.5 -1.21 1.3E-
02
0.42 0.61 1.78 1.9E-
03
IL8 chr4:74606222–
74609433
0.87 4.31 0.09 0.16 2.31 1.9E-
03
-3.22 1.9E-
03
-4.79 1.9E-
03
doi:10.1371/journal.pone.0134057.t005
Fig 2. Vitamin D and TNFα Responsiveness of CCL2,CCL13,CXCL12, and IL8 by qRT-PCR using theGABARAP housekeeping gene as reference.
doi:10.1371/journal.pone.0134057.g002
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secretion was significantly higher in fatal asthma- vs. non-asthma-derived ASM. Although
vitamin D was an effective inhibitor of TNFα-induced cytokine secretion, none of the TNFα-
induced cytokine levels were completely abrogated. Further, the amount of TNFα-induced
cytokine inhibition by vitamin D differed among cytokines, with IL8 levels being inhibited the
least in fatal asthma- and non-asthma-derived ASM cells.
Discussion
Previous studies have focused on understanding the potential therapeutic role of vitamin D in
asthma because lower vitamin D levels are associated with increased asthma exacerbations and
anti-inflammatory medication use, and decreased lung function [7,15]. A major mode of vita-
min D (1,25(OH)2D3) action is to directly alter the expression of genes [16]. Understanding
the role of vitamin D in modifying the ASM transcriptome of fatal asthma patients may thus
provide insights into the mechanisms by which vitamin D influences severe asthma. Our
RNA-Seq results found that a large number of genes are differentially expressed in the ASM
of fatal asthma vs. non-asthma donors, and that the responsiveness to vitamin D treatment dif-
fers between these two groups. Vitamin D treatment of both fatal asthma- and non-asthma-
derived ASM resulted in the differential expression of many cytokines and chemokines, but
Fig 3. TNFα-induced cytokine levels in ASM. Cytokine levels in supernatant obtained from ASM derived from fatal asthma and non-asthma donors were
determined by single ELISA. The data represent means ± standard error from ASM cells of 3 fatal asthma and 3 non-asthma donors for CCL2 and CXCL12; 5
fatal asthma and 6 non-asthma donors for CCL13; and 5 fatal asthma and 5 non-asthma donors for IL8 (numbers based on availability of cells used after
RNA-Seq experiments). Each observation was performed in triplicate. Statistical significance was determined by Student’s one-tailed t-test with significance
determined at p<0.05.
doi:10.1371/journal.pone.0134057.g003
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corresponding ontological categories were not found to be over-represented in the baseline
comparison between fatal asthma- and non-asthma-derived ASM. Vitamin D receptor (VDR)
mRNA expression levels were not different between fatal asthma- and non-asthma derived
ASM [S3 Fig], suggesting that gene expression differences between these groups in response to
vitamin D treatment did not simply reflect vitamin D sensitivity differences proportional to
vitamin D receptor availability.
We chose to focus our functional studies on four cytokines that were differentially expressed
between fatal asthma- and non-asthma-derived ASM and were also modified by vitamin D
treatment in fatal asthma-derived ASM (i.e., CCL2, CCL13, CXCL12, IL8). While each of these
genes was differentially expressed in fatal asthma- vs. non-asthma-derived ASM at baseline
and with vitamin D treatment in fatal asthma-derived ASM, expression variability across sam-
ples was evident [Fig 1]. Subsequent qPCR results did not replicate RNA-Seq differential
expression between fatal asthma- and non-asthma-derived ASM at baseline, and were only
partly consistent with vitamin D effects: consistent with RNA-Seq results, CCL2 had decreased
and CXCL12 had increased mRNA with vitamin D treatment for most samples, while CCL13
and IL8manifested opposite mean effects [Fig 2]. These disparate findings could be due to
inter-individual variability, unaccounted for experimental error by either RNA-Seq or qPCR,
limitations in the methods used to analyze RNA-Seq data, and/or the intrinsic differences in
the experimental techniques. In the case of CCL13 and IL8, mRNA expression levels were
low as evidenced by having most RNA-Seq FPKM values<10, which may have contributed
toward inconsistency in measures between RNA-Seq and qPCR, as results from lowly
expressed genes are known to be more error prone [30]. There is no consensus about the opti-
mal way to analyze RNA-Seq data and considerable variability in results obtained based on
platform and data analysis pipeline has been observed [31]. While RNA-Seq measures for each
condition were normalized by taking some global measures into account (e.g., the total number
of reads that mapped to the reference genome), qPCR measures were obtained in reference to a
Fig 4. Vitamin D inhibited TNFα-induced cytokine expression. Although the amount of inhibition differed by cytokine, vitamin D inhibited three cytokine
levels to a comparable degree in fatal asthma-derived vs. non-asthma-derived ASM, even for IL8, whose TNFα-induced baseline secretion was significantly
higher in fatal asthma- vs. non-asthma-derived ASM. Data represent means ± standard error of the mean for ASM cells derived from 5 fatal asthma donors
and 10 non-asthma donors. Each condition was measured in triplicate. Statistical significance was determined using Student’s two-tailed t-test with a p<0.05
threshold. Bottom panels compare baseline TNFα-induced cytokine levels to those obtained with a maximal inhibitory vitamin D concentration (Imax).
doi:10.1371/journal.pone.0134057.g004
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housekeeping gene only. We selected GABARAP as a housekeeping gene after finding that its
coefficient of variation, 23.52%, was lowest among that of four genes (i.e. ACTB,HPRT1,
GABARAP, RPL19) [S4 Fig]. Repetition of qPCR results using ACTB as a housekeeping gene
found that similar trends emerged as when using GABARAP as reference, despite GABARAP
having a greater coefficient of variation (47.92%) [S5 Fig]. We selected the housekeeping gene
with lowest amount of variation to minimize the impact that its variability of expression would
have on our ability to measure changes in the expression of other genes of interest. However,
because a housekeeping gene with even greater coefficient of variability yielded similar results,
the housekeeping gene choice may not have been the main source of inconsistency between
RNA-Seq and qPCR results. Further sequencing and qPCR experiments using a greater num-
ber of individuals may clarify the source of inconsistency between techniques.
Comparison of RNA and protein expression for the four cytokines in Figs 1 and 3 shows (1)
decreased CXCL12 mRNA, protein secretion at baseline, and TNFα-induced protein secretion
in fatal asthma- vs. non-asthma-derived ASM, (2) increased CCL2 mRNA, protein secretion at
baseline, and TNFα-induced protein secretion in fatal asthma- vs. non-asthma-derived ASM,
although the protein secretion results are not statistically significant, (3) increased IL8 mRNA
and TNFα-induced protein secretion in fatal asthma- vs. non-asthma-derived ASM, but unde-
tectable levels of protein secretion at baseline, and (4) increased CCL13 mRNA in fatal asthma-
vs. non-asthma-derived ASM, but unchanged protein secretion levels. Comparison of TNFα-
induced mRNA and protein expression levels of for the four cytokines in Figs 2 and 3 shows
that CCL2, CCL13, and IL8 had increased levels in both fatal asthma- and non-asthma-derived
ASM, while CXCL12 had decreased levels in all but a few qPCR samples. Thus, consistency
between mRNA and protein secretion levels is high for TNFα-induced changes, and present to
varying degrees among the four cytokines for changes between fatal asthma- and non-asthma-
derived ASM, with CXCL12 and IL8 showing the greatest consistency and CCL13 the weakest.
While sometimes the levels of mRNA correlate with those of protein secretion, there are vari-
ous stages between transcription and protein secretion that could bar a simple relationship,
including protein translation, post-translational modifications that activate proteins and/or
avoid degradation, and processes that successfully export protein from cells [32,33]. Based on
our results, CCL2, CXCL12, and IL8 may have correlated mRNA and protein secretion levels
that differ between fatal asthma- and non-asthma-derived ASM, but the difference in IL8 may
only be noticeable with TNFα induction due to its low baseline levels. The mRNA differences
of CCL13 between fatal asthma- and non-asthma-derived ASM did not extend to protein
secretion levels. Further studies that address in more depth the mechanisms by which cytokine
mRNA changes lead to protein level and secretion differences are needed to support our
observed correlations for CCL2, CXCL12, and IL8.
The CCL2, CCL13, CXCL12, and IL8 cytokine genes selected for experimental follow-up are
known to be involved in asthma related processes. A previous study found that CCL2 (aka
MCP1) concentration was elevated in primary ASM supernatant and blood of asthma patients,
its sputum levels were increased in asthma patients with bronchial wall thickening, and chemo-
taxis assays suggested that it mediates fibrocyte migration toward ASM [34]. CCL2 has also
been found to promote mast cell recruitment [35] and Th17 cell migration [36] to the lung in
mouse models of asthma. CCL13 (aka MCP4) is a monocyte chemoattractant that has been
proposed as a biomarker of asthma because its levels were higher in plasma of (1) asthma
patients vs. non-asthma controls and (2) asthma patients with acute exacerbations vs. stable
asthma [37], and its receptor, CCR3, has been shown to induce migration of ASM cells in vitro
[38]. CXCL12, a chemotactic factor with pleiotropic effects that are modulated by cofactors,
recruits cell types including leukocytes [39] and mast cells [40]. A potential asthma therapeutic
based on blocking of CXCL12 has been shown to reduce airway eosinophil recruitment in an
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ovalbumin mouse model of asthma [41]. Further, airway mucosa from asthma patients had a
greater number of CXCL12 (aka SDF1) positive cells than that from healthy subjects, and the
number of CXCL12+ cells correlated with vascularity, suggesting that CXCL12 may play a role
in airway remodeling [42]. Finally, IL8 is a neutrophil chemoattractant whose levels have been
reported to be elevated in the sputum of asthma patients, suggesting that it may play a role in
severe asthma that is characterized by neutrophilia [43,44]. Our RNA-Seq results showing that
CCL2, CCL13, and IL8mRNA levels were elevated in fatal asthma-derived ASM are consistent
with these previous studies showing elevated levels in ASM (for CCL2) and other tissues. Our
RNA-Seq results for CXCL12 showing decreased mRNA levels in fatal asthma have an opposite
effect from that expected based on increased CXCL12+ cell types in airway mucosa, but a direct
comparison of these studies’ results is limited because of the different experimental designs.
Our work extends what is known about these four cytokines by suggesting a potential role of
vitamin D in regulating their levels in ASM. However, dysregulation of these cytokines is a
complex process with high variability across individuals, and further studies are required to
better understand the mechanisms by which vitamin D may modulate their effects.
Changes in expression and secretion of individual genes in ASM cells in response to vitamin
D treatment have been studied previously. For example, in a study of the inhibitory properties
of vitamin D on ASM proliferation,MMP9 and ADAM33 were selected as candidate genes via
which vitamin D might affect ASM hyperplasia and both were differentially expressed with
vitamin D treatment [14]. In our results, these genes were not differentially expressed in either
of the three comparisons made, but other genes representing the extracellular matrix were sig-
nificantly represented, including other matrix metalloproteinases (e.g.,MMP1,MMP12) and
ADAMTS proteases (e.g., ADAMTS10, ADAMTS15) [S5 and S6 Tables]. A previous study of
the role of vitamin D in ASM inflammation found that vitamin D decreased expression of
KPNA4 (a.k.a. importin α3), a mediator of NFκB-induced inflammation, by TNFα and IL1β in
the ASM [12], but in our study, KPNA4mRNA was not differentially expressed in any of the
comparison groups. Another study found that TNFα/IFNγ-induced secretion of CX3CL1 was
significantly decreased by vitamin D treatment [11]. Consistent with this result, we found that
CX3CL1 expression was decreased in non-asthma-derived ASM treated with vitamin D vs. at
baseline (q-value 0.011; log2 fold-change 2.3), but the findings did not hold in fatal asthma-
derived ASM. TNFα-induced CCL5 (aka RANTES) and CXCL10 (aka IP-10) chemokine secre-
tion were decreased in ASM cells treated with vitamin D [11], but we did not observe any
mRNA expression changes for CCL5 or CXCL10. These differences between protein secretion
and transcript expression suggest that some changes in cytokine secretion levels are not tran-
scriptionally mediated, or that stimulation with an appropriate cytokine is necessary to observe
the changes.
On a transcriptomic level, the effects of vitamin D on ASM gene expression were measured
in a previous microarray study that used cells from a single non-asthmatic male donor stimu-
lated with 100nM 1α,25(OH)2D3 for 24 hours [17]. Our results are consistent with the results
reported in that paper. For example, CDC42EP3, CEBPB, G6PD,HSD11B1, IL6, and ITPR1
were highlighted by this previous study as asthma-relevant genes that were differentially
expressed in response to vitamin D treatment, and each of these is among the 394 genes with
lowest q-value of 1.92E-03 in our baseline vs. vitamin D treated non-asthma-derived ASM
comparison [S7 Table]. A subset of these genes (i.e., CDC42EP3, ITPR1, G6PD) was differen-
tially expressed in the fatal asthma- vs. non-asthma-derived ASM at baseline comparison,
while a different subset (i.e., CEBPB, CDC42EP3, ITPR1, and HSD11B1) was differentially
expressed in fatal asthma-derived ASM when stimulated with vitamin D vs. left untreated [S7
Table]. The differences in significant genes among comparison groups may reflect biological
differences in vitamin D responsiveness between fatal asthma- and non-asthma-derived ASM
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cells. Thus, an important strength of our study compared to previous reports is the inclusion of
ASM cells from diseased individuals, which may aid in identifying transcriptomic differences
that are most relevant to asthma.
The ontological categories represented by differentially expressed genes in S1, S3, and S4
Tables are consistent with biological processes known to be important in severe asthma. The
extracellular matrix is important in ASM remodeling [45], steroid resistance and oxidative
stress directly contribute to severe asthma [6], and differences in lung development and
response to wounding may contribute to intrinsic differences in ASM that alter asthma sever-
ity. Two categories that were not over-represented by differentially expressed genes but might
be expected are those related to smooth muscle contraction and smooth muscle proliferation
since the ASM regulates airway contractility and ASM proliferation contributes to increased
ASMmass [45]. Although statistical significance was not achieved, categories related to these
processes characteristic of smooth muscle function were represented by genes significantly dif-
ferentially expressed in some comparisons. Specifically, GO:0048661~positive regulation of
smooth muscle cell proliferation included seven differentially expressed genes (i.e. PRKCA, IL6,
S1PR1, PTGS2, VEGFA, IGF1, ITGA2) in non-asthma-derived ASM and six differentially
expressed genes (i.e. CDH13, VEGFA, TGM2, IGF1, ITGA2, STAT1) in fatal asthma-derived
ASM, with Benjamini-Hochberg corrected p-values of 0.066 and 0.14, respectively. This cate-
gory was absent in the fatal asthma- vs. non-asthma-derived ASM baseline comparison. The
category GO:0006939~smooth muscle contraction included four differentially expressed genes
(i.e., ACTG2, EDNRB, AGT,MYH11) in the fatal asthma- vs. non-asthma-derived ASM com-
parison, six differentially expressed genes (i.e., KCNMA1, EDNRB, CACNA1G, BDKRB2, CAC-
NA1C, GDNF) in the non-asthma-derived ASM baseline vs. vitamin D treatment comparison,
and four differentially expressed genes (i.e., KCNMA1, EDNRA, ACTG2, AGT) in the fatal
asthma-derived ASM baseline vs. vitamin D treatment comparison, with Benjamini-Hochberg
corrected p-values of 0.80, 0.22 and 0.69, respectively. Thus, while groups of genes of some rele-
vant ontological categories may not have been differentially expressed, transcriptional changes
of individual genes that influence ASM contractility and proliferation were present.
A limitation of our study is that we used ASM cells from white donors to study responsive-
ness to vitamin D. Dose response rates [46] and vitamin D protein binding levels [47] by race,
suggesting that gene expression differences in response to vitamin D treatment also differ by
race. Because vitamin D deficiency [48] and asthma prevalence, hospitalizations, and death
rates [49] are known to be higher among black than white patients, future studies of the effect
of vitamin D on the ASM transcriptome that include individuals of diverse racial/ethnic back-
grounds may reveal additional gene candidates and/or biological pathways that shed light on
asthma disparities. Another limitation is that our RNA-Seq analyses were limited to the hg19
RefSeq annotation files downloaded from Illumina’s iGenomes project. Thus, we did not char-
acterize the expression of long-non-coding RNA or mRNA transcript isoforms that were not
part of the reference file used. We opted for use of a well-annotated reference file for our inves-
tigation of the ASM transcriptome to reduce the number of false-positive results. Future studies
with more comprehensive annotation files, a greater number of individuals, and/or greater
sequencing depth will yield additional insight into the ASM transcriptome.
In summary, we found that 838 genes were differentially expressed in fatal asthma- vs. non-
asthma-derived ASM at baseline, and vitamin D treatment vs. baseline conditions resulted in
differential expression of 867 and 711 genes in non-asthma- and fatal asthma-derived ASM,
respectively. Functional categories that were represented in all groups include extracellular
matrix, response to steroid hormone stimulus, and response to wounding. Genes differentially
expressed by vitamin D also represented cytokine and chemokine activity categories. Further
experiments conducted for four cytokines (i.e. CCL2, CCL13, CXCL12, IL8) selected from
Vitamin D Modulates Airway Smooth Muscle Transcriptome
PLOSONE | DOI:10.1371/journal.pone.0134057 July 24, 2015 18 / 26
among the top RNA-Seq results found that vitamin D inhibited TNFα-induced IL8 protein
secretion levels to a comparable degree in fatal asthma- and non-asthma-derived ASM even
though IL8 had significantly higher baseline levels in fatal asthma-derived ASM. Our results
provide transcriptome data to further explore the functional differences in the ASM of fatal
asthma vs. non-asthma donors, as well as differences in their vitamin D responsiveness.
Materials and Methods
Ethics Statement
Lung tissue was obtained from the National Disease Resource Interchange (NDRI) and its use
approved by the University of Pennsylvania Institutional Review Board; use of the cells does
not constitute human subjects research since all donor tissue is harvested anonymously and
de-identified.
ASMCell Culture and Vitamin D Treatment for RNA-Seq Experiment
Primary ASM cells were isolated from white donors, six who died of fatal asthma and ten with
no chronic illness or medication use. ASM cell cultivation was described previously [50,51].
ASM cells up to passage 4 maintained in Ham's F12 medium supplemented with 10% FBS,
CaCl2, buffered with HEPES, penicillin/streptomycin, primocin, and additional L-glutamine
were used in all experiments. The F12 medium was used for culture because it provides Ca2+
levels that are consistent with seeing contractility of muscles in that media. Following 48 hours
of serum deprivation, cells from each donor were treated with 100 nM vitamin D (1,25
(OH)2D3, Cayman Chemical Company, Ann Arbor, MI) or control vehicle for 18 h. This treat-
ment protocol is biologically relevant (approximately 80μg/dL of vitamin D), maximally
induces expression of CYP24A1, a well-known metabolizer of vitamin D, and inhibits cyto-
kine-induced cytokine and chemokine expression in ASM [11,13].
RNA-Seq Library Construction and Sequencing
Total RNA was extracted from cells using the miRNAeasy mini kit (Qiagen Sciences, Inc., Ger-
mantown, MD). Approximately 1 μg of RNA from each sample was used to generate RNA-Seq
cDNA libraries for sequencing using the TruSeq RNA Sample Prep Kit v2 (Illumina, Inc., San
Diego, CA). Sample preparation followed the manufacturer’s protocol with a workflow that
included isolation of poly-adenylated RNA molecules using poly-T oligo-attached magnetic
beads, enzymatic RNA fragmentation, cDNA synthesis, ligation of bar-coded adapters, and
PCR amplification. Ambion External RNA Controls Consortium (ERCC) RNA Spike-In Con-
trol Mix 1 (Life Technologies Corporation, Carlsbad, CA) was added to the samples. The
amplified cDNA fragments were analyzed using the 2100 Bioanalyzer (Agilent Technologies,
Inc., Santa Clara, CA) to determine fragment quality and size. Library concentrations were
determined by Qubit Fluorometric Quantitation (Life Technologies Corporation, Carlsbad,
CA). Sequencing of 75 bp paired-end reads was performed with an Illumina HiSeq 2000 instru-
ment at Partners Personalized Medicine (Boston, MA).
RNA-Seq Data Analysis
Preliminary processing of raw reads was performed using Casava 1.8 (Illumina, Inc., San
Diego, CA). Subsequently, Taffeta scripts (https://github.com/blancahimes/taffeta) were used
to analyze RNA-Seq data, which included trimming of adapters using trimmomatic (v.0.22)
[52] and using FastQC [53] (v.0.10.0) to obtain overall QC metrics. Trimmed reads for each
sample were aligned to the reference hg19 genome and known ERCC transcripts using TopHat
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[54] (v.2.0.8), while constraining mapped reads to be within reference hg19 or ERCC tran-
scripts. Additional QC parameters were obtained to assess whether reads were appropriately
mapped. Bamtools (v.1.0.2) [55] was used to count/summarize the number of mapped reads,
including junction spanning reads. The Picard Tools (v.1.58; http://picard.sourceforge.net)
RnaSeqMetrics function was used to compute the number of bases assigned to various classes
of RNA, according to the hg19 refFlat file available as a UCSC Genome Table. For each sample,
Cufflinks [18] (v.2.1.1) was used to quantify ERCC Spike-In and hg19 transcripts based on
reads that mapped to the provided hg19 and ERCC reference files. ERCC Spike-ins dose
response curves (i.e. plots of ERCC transcript FPKM vs. ERCC transcript molecules) were cre-
ated following the manufacturer’s protocol [56]. Raw read plots were created by displaying big-
wig files for each sample in the UCSC Genome Browser. The RNA-Seq data is available at the
Gene Expression Omnibus Web site (http://www.ncbi.nlm.nih.gov/geo/) under accession
GSE58434.
RNA-Seq Quality Control
Initially, 36 RNA samples from 18 vitamin D treated and untreated pairs were obtained. One
pair of RNA samples was excluded from sequencing preparation due to failed RIN scores, indi-
cating very low RNA quality. Two samples with evidence of poor quality RNA-Seq library
(based on low percentage of junction spanning reads, percentage of mRNA bases and mean
insert size [S8 Table]) and the two paired samples matching them, were also excluded, leaving
a total of 30 samples selected for differential expression analysis. Such samples corresponded to
5 fatal asthma and 10 non-asthma-derived donors with vitamin D or control vehicle treatment
[Table 1]. For these 30 samples, we obtained an average of 93.2 million raw sequencing reads
per sample (range 73.0–121.7 million reads per sample). Of these reads, an average of 89.1%
were aligned to hg19 genome reference files downloaded from Illumina’s iGenomes project
(range 85.9%-91.6%), and an average of 29.1% of the mapped reads spanned junctions (range
23.2%-31.4%). An average of 92.7% of bases in mapped reads corresponded to mRNA (range
73.6%-96.2%). ERCC spike-in dose response plots, which ideally would have slope and R2
equal to 1.0, had slope and R2> = 0.91. Based on these and other quality control (QC) sum-
mary metrics, the sequencing and alignment results for each of the 30 samples were deemed of
sufficiently high quality to include in differential expression analyses [S8 Table]. Quantification
of transcript and gene expression levels, according to hg19 RefSeq annotation files from Illumi-
na’s iGenomes Project, was performed using Cufflinks. As positive controls of gene expression,
fragments per kilobase of transcript per million mapped reads (FPKM) values for three house-
keeping genes (i.e., B2M, GABARAP, RPL19), one well known metabolizer of vitamin D (i.e.,
the cytochrome P450 gene CYP24A1 [57]), and the vitamin D receptor (i.e., VDR) were
obtained. Each housekeeping gene had high FPKM values that did not differ significantly by
treatment status, CYP24A1’s barely detectable baseline levels greatly increased in response to
vitamin D treatment [S2 Fig], and VDR had a trend toward increase in response to vitamin D
treatment but did not differ significantly by treatment or fatal asthma vs. non-asthma status
[S3 Fig].
Differential expression of genes and transcripts was obtained using Cuffdiff [18] (v.2.1.1) with
the quantified transcripts computed by Cufflinks (v.2.1.1), while applying bias correction for all
samples. The CummeRbund [58] R package (v.2.0.0) was used to measure significance of differ-
entially expressed genes and create plots of the results. The reported q-values are false-discovery
rate adjusted p-values according to the implementation in Cuffdiff and CummeRbund that take
into account the large number of comparisons made. Comparison groups of interest were: 1)
fatal asthma- vs. non-asthma-derived ASM samples at baseline; 2) fatal asthma-derived ASM
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samples treated with vitamin D vs. left untreated; 3) non-asthma-derived ASM samples treated
with vitamin D vs. left untreated. The NIH Database for Annotation, Visualization and Inte-
grated Discovery (DAVID) was used to perform gene functional annotation clustering using
Homo Sapiens as background, and default options and annotation categories (Disease:
OMIM_DISEASE; Functional Categories: COG_ONTOLOGY, SP_PIR_KEYWORDS, UP_
SEQ_FEATURE; Gene_Ontology: GOTERM_BP_FAT, GOTERM_CC_FAT, GOTERM_
MF_FAT; Pathway: BBID, BIOCARTA, KEGG_PATHWAY; Protein_Domains: INTERPRO,
PIR_SUPERFAMILY, SMART) [29].
Quantitative Real-Time PCR (qRT-PCR) Analysis
Following 48 hours of serum deprivation, ASM cells from 4 fatal and 10 non-asthma-derived
donors (all used for RNA-Seq) were treated with 100nM vitamin D or vehicle control for 1h,
followed by stimulation with 10ng/mL TNFα or vehicle control for 18h. Total RNA was iso-
lated from cells by using QIAshredder and RNeasy kits (Qiagen Sciences, Inc., Germantown,
MD). Oligo(dT)-primed cDNA was prepared from 500 ng of total RNA by using SuperScript
III First-strand Synthesis System (Invitrogen, Life Technologies, Grand Island, NY). qRT-PCR
was set up in the presence of 0.5 μM primers for CCL2, CCL13, CXCL12, and IL8 by using
QuantiTect SYBR Green PCR kit (Qiagen Sciences, Inc., Germantown, MD). qRT-PCR was
performed on an Eppendorf Mastercycler ep Realplex2 real time PCR machine (Eppendorf,
Hauppauge, NY). GABARAP was used as an internal control for data normalization as it was
the housekeeping gene with the lowest amount of variation among six ASM samples (3 fatal
asthma-derived, 3 non-asthma-derived) for four housekeeping genes tested (i.e. ACTB,
HPRT1, GABARAP, RPL19) [S4 Fig]. Additionally, we repeated qRT-PCR using ACTB as a
housekeeping gene to measure the extent of result variability given the housekeeping gene
choice [S5 Fig]. Fold increase of expression was calculated using the delta-delta CT method.
Cytokine ELISAs
To test whether some of our RNA-Seq results extended to protein secretion levels, ELISAs were
performed for four cytokines. Human ASM cells were grown to confluence and then serum
deprived for 48 h. Monolayers were stimulated with 10 ng/ml TNFα (Roche Diagnostics Cor-
poration, Indianapolis, IN), in the presence and absence of 100 nM vitamin D, or vehicle con-
trol. After an 18h incubation, supernatants were harvested and cytokine or chemokine levels
measured by single analyte ELISAs (R&D Systems, Minneapolis, MN). Comparisons were
made of baseline and TNFα-induced chemokine and cytokine levels in fatal asthma-derived
ASM and those derived from non-asthma age- and gender-matched donors. Analyses were
performed using ASM cells from 3 fatal asthma and 3 non-asthma donors for CCL2 and
CXCL12; 5 fatal asthma and 6 non-asthma donors for CCL13; and 5 fatal asthma and 5 non-
asthma donors for IL8 based on availability of cells used after RNA-Seq experiments. Each con-
dition was performed in triplicate. Data was analyzed as means ± standard error of the means
and statistics determined significance using one-tailed student’s t test.
Supporting Information
S1 Fig. RNA-Seq profiling of ASM cells. Volcano plots of overall gene-based differential
expression results for A) fatal asthma- vs. non-asthma-derived ASM at baseline, B) non-
asthma-derived ASM at baseline vs. when treated with vitamin D, C) fatal asthma-derived
ASM at baseline vs. when treated with vitamin D. The y-axis corresponds to the negative log
(base 10) of P-values while the x-axis corresponds to the negative log (base 2) of the fold change
for difference in expression between categories. Differentially expressed genes according to an
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adjusted p-value<0.05 are colored in red.
(TIFF)
S2 Fig. RNA-Seq results expressed as FPKM for three housekeeping genes (i.e., B2M,
GABARAP, RPL19) and one well known metabolizer of vitamin D (i.e., the cytochrome
P450 gene CYP24A1) by condition status show (1) high levels of expression for each house-
keeping gene that did not significantly differ by condition status, and (2) induction of
CYP24A1 with vitamin D treatment in both fatal asthma- and non-asthma-derived ASM
cells.
(TIFF)
S3 Fig. RNA-Seq results expressed as FPKM for the vitamin D receptor gene (i.e., VDR) by
condition status show that its mRNA levels did not significantly differ by condition status.
(TIFF)
S4 Fig. Variation in 2^[-Ct] values for four housekeeping genes (i.e., ACTB,HPRT1,
GABARAP, RPL19) among six ASM samples (3 fatal asthma-derived, 3 non-asthma-
derived). GABARAP was selected as a reference housekeeping gene for further qPCR experi-
ments.
(TIFF)
S5 Fig. Vitamin D and TNFα Responsiveness of CCL2, CCL13, CXCL12, and IL8 by
qRT-PCR using ACTB as a housekeeping reference gene shows similar differential expres-
sion results as those in Fig 2.
(TIFF)
S1 Table. Functional annotation clusters obtained with the NIH DAVID tool using all dif-
ferentially expressed genes in fatal asthma- vs. non-asthma-derived ASM at baseline. Clus-
ters with enrichment scores>1.5 are shown. Individual P-values listed correspond to EASE
Scores, or modified Fisher Exact P-Values computed by DAVID.
(DOCX)
S2 Table. Individual annotation categories for top 838 fatal asthma- vs. non-asthma-
derived ASM differentially expressed genes obtained from NIH DAVID cluster analysis
tool. Categories selected were from clusters with enrichment scores>2.50 and with individual
Benjamini-Hochberg corrected p-values<0.05 that correspond to known asthma-related
structures and processes, plus two categories that met these criteria in the vitamin D treated
cells vs. those at baseline. Genes listed were the differentially expressed ones for the corre-
sponding category.
(DOCX)
S3 Table. Functional annotation clusters obtained with the NIH DAVID tool using all dif-
ferentially expressed genes in non-asthma-derived ASM at baseline vs. when treated with
vitamin D. Clusters with enrichment scores>1.5 are shown. Individual P-values listed corre-
spond to EASE Scores, or modified Fisher Exact P-Values computed by DAVID.
(DOCX)
S4 Table. Functional annotation clusters obtained with the NIH DAVID tool using all dif-
ferentially expressed genes in fatal asthma-derived ASM at baseline vs. when treated with
vitamin D. Clusters with enrichment scores>1.5 are shown. Individual P-values listed corre-
spond to EASE Scores, or modified Fisher Exact P-Values computed by DAVID.
(DOCX)
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S5 Table. Individual annotation categories for top 867 non-asthma-derived ASM at base-
line vs. with vitamin D treatment differentially expressed genes obtained from NIH
DAVID cluster analysis tool. Categories selected were from clusters with enrichment scores
>2.50 and with individual Benjamini-Hochberg corrected p-values<0.05 that correspond to
known asthma-related structures and processes, plus categories that met these criteria in
Table 3. Genes listed were the differentially expressed ones for the corresponding category.
(DOCX)
S6 Table. Individual annotation categories for top 711 fatal asthma-derived ASM at base-
line vs. with vitamin D treatment differentially expressed genes obtained from NIH
DAVID cluster analysis tool. Categories selected were from clusters with enrichment scores
>2.50 and with individual Benjamini-Hochberg corrected p-values<0.05 that correspond to
known asthma-related structures and processes, plus categories that met these criteria in
Table 3. Genes listed were the differentially expressed ones for the corresponding category.
(DOCX)
S7 Table. Differential expression results for all comparison groups of asthma-related genes
that were differentially expressed in ASM cells from a single male donor treated with vita-
min D highlighted in previous work by Bosse, Y et al [17].
(DOCX)
S8 Table. RNA-Seq Metrics Computed for Quality Control. The table contains the number
of raw reads for the paired-end samples, the percentage of mapped reads among the total num-
ber of raw reads, the percentage of junction spanning reads among the mapped reads, the per-
centage of mapped bases that mapped to mRNA, the mean insert size of mapped reads, and the
slope and R2 values of ERCC spike-in dose response curves. Samples that were not included in
differential expression analyses are highlighted in grey. The two samples marked by an asterisk
() were dropped because of low percentage of junction spanning reads and mRNA bases, and
mean insert size. The other three samples highlighted in grey were dropped because their pairs
were not successfully sequenced.
(DOCX)
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